Should you buy Abbott Laboratories stock now?
The technical signal for Abbott Laboratories is currently NEUTRAL. Abbott Laboratories trades at $106.54 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 3.816 with rising momentum (signal: 3.614); RSI is at 64.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $118.42 points to 11.2% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Abbott Laboratories stock?
The average analyst price target for Abbott Laboratories is $118.42. The current price is $106.54, which gives an upside of 11.2%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $106.58 and $130.26.
Is Abbott Laboratories a dividend stock?
Yes, Abbott Laboratories is a dividend stock with a dividend yield of 2.32%. The latest dividend was $0.63 per share. The latest ex-dividend date (traded without the dividend) was 7/15/2026. The payout ratio is 47.2%, which is considered sustainable. The next dividend payment is scheduled for 8/17/2026.
When does Abbott Laboratories pay a dividend in 2026?
Abbott Laboratories pays its next dividend on 8/17/2026. The latest dividend was $0.63 per share with an ex-dividend date of 7/15/2026. The dividend yield is 2.32%. The payout ratio of 47.2% points to a sustainable dividend with room to grow.
What is the risk of Abbott Laboratories stock?
Abbott Laboratories is rated as a stock with moderately low risk. the annual standard deviation is 26.5%, which classifies the stock as moderately low risk.
Is Abbott Laboratories overvalued?
No, Abbott Laboratories is considered undervalued based on the analyst price target (11.2% upside). Abbott Laboratories has the following valuation ratios: a P/E ratio of 34.1 (highly valued), a P/S ratio of 3.9, a P/B ratio of 3.6. The analyst price target suggests that the stock is undervalued by 11.2%.
Is Abbott Laboratories overbought?
No, Abbott Laboratories is not overbought. RSI is at 64.6 (neutral zone). The technical indicators show: RSI is at 64.6 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 6.0% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Abbott Laboratories earnings report?
Abbott Laboratories reports its next earnings on October 14, 2026. The stock currently trades at $106.54. With a P/E ratio of 34.1, the market will be watching closely whether earnings meet expectations.
Is Abbott Laboratories shorted?
Yes, Abbott Laboratories is shorted with 1.6% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Abbott Laboratories stock?
No, insiders are not buying Abbott Laboratories shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 2 sales. On a net basis, 77,646 $ worth of shares were sold. Across the last 20 reported transactions, the split is 4 purchases and 16 sales, with a net 9,970 $ sold. Active sellers include Morrone Louis H., Cushman Elizabeth C., Shroff Eric and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Abbott Laboratories a good stock?
Based on our total score, Abbott Laboratories is rated as a mediocre stock with a total score of 53 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 40/100, Quality: 67/100, Momentum: 51/100. In addition: analysts see 11.2% upside to the price target; a dividend of 2.32%; technical signal: Hold. Whether Abbott Laboratories is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Abbott Laboratories stock?
The outlook for Abbott Laboratories based on current data: the average analyst price target is $118.42 (+11.2%); the next earnings report is due on 10/14/2026, which can move the price; the P/E ratio is 34.1 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Abbott Laboratories stock rising?
Abbott Laboratories is rising right now. The technical indicators show: the price is 6.0% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Abbott Laboratories go?
The average analyst price target for Abbott Laboratories is $118.42, which corresponds to a potential gain of 11.2% from the current price of $106.54. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Abbott Laboratories fall?
We lack enough history to give a specific floor for Abbott Laboratories. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Abbott Laboratories do?
Abbott Laboratories laver og sælger sundhedsprodukter over hele verden. De tjener penge på fire store områder: medicin, diagnostik, ernæring og medicinsk udstyr. Abbott udvikler for eksempel generisk medicin til behandling af lidelser som irritabel tyktarm, men også anti-infek... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Abbott Laboratories as an investment.
Did Abbott Laboratories raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Abbott Laboratories. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Abbott Laboratories making money or losing money?
Yes, Abbott Laboratories is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 11.7% — which is solid. The operating margin (profit before interest and taxes) is 14.7%. At a P/E ratio of 34.1, you currently pay 34.1 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Abbott Laboratories go bankrupt?
The bankruptcy risk of Abbott Laboratories is rated as low. Altman Z2 (a model for assessing financial distress) is 3.35 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 70% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Abbott Laboratories have a lot of debt?
No, Abbott Laboratories has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 70%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
